dystrophies Pediatr Cardiol 2005;26(1):66–72 226 Markham LW, Michelfelder EC, Border WL, et al Abnormalities of diastolic function precede dilated cardiomyopathy with duchenne muscular dystrophy J Am Soc Echocardiogr 2006;19(7):865–871 227 Ogata H, Nakatani S, Ishikawa Y, et al Myocardial strain changes in duchenne muscular dystrophy without overrt cardiomyopathy Int J Cardiol 2007;115(2):190–195 228 Matsumura T, Saito T, Fujimura H, Shinno S Cardiac troponin I for accurate evaluation of cardiac status in myopathic patients Brain Dev 2007 [Epub ahead of print] 229 Ramaciotti C, Heistein LC, Coursey M, et al Left ventricular function and response to enalapril in patients with duchenne muscular dystrophy during the second decade of life Am J Cardiol 2006;98(6):825–827 230 Duboc D, Meune C, Lerebours G, et al Effect of perindopril on the onset and progression of left ventricular dysfunction in duchenne muscular dystrophy J Am Coll Cardiol 2005;45(6):855– 857 231 Kajimoto H, Ishigaki K, Okumura K, et al Betablocker therapy for cardiac dysfunction in patients with muscular dystrophy Circ J 2006;70(8):991–994 232 Evans T Cardiac abnormalities associated with hereditary neuromuscular diseases Symons C, Evans T Specific Heart Muscle Disease PSG Wright: Boston; 1983:46–61 233 Sanyal SK, Johnson WW Cardiac conduction abnormalities in children with Duchenne's progressive muscular dystrophy: electrocardiographic features and morphologic correlates Circulation 1982;66:853–863 234 Shimizu-Motohashi Y, Miyatake S, Komaki H, Takeda S, Aoki Y Recent advances in innovative therapeutic approaches for duchenne muscular dystrophy: from discovery to clinical trials Am J Transl Res 2016;8(6):2471–2489 235 Bonuccelli G, Sotgia F, Capozza F, et al Localized treatnebt with a novel FDA-approved proteasome inhibitor blocks the degradation of dystrophin-associated proteins in mdx mice Cell Cycle 2007;6(10):1242–1248 236 Townsend D, Yasuda S, Metzger J Cardiomyopathy of duchenne muscular dystrophy: pathogenesis and prospect of membrane sealants as a new therapeutic approach Expert Rev Cardiovasc Ther 2007;5(1):99–109 237 Quenneville SP, Chapdelaine P, Skuk D, et al Autologous transplantation of muscle precursor cells modified with a lentivirus for muscular dystrophy: human cells and rimate models Mol Ther 2007;15(2):431–438 238 Ben Yaou R, Becane HM, Demay L, et al Autosomal dominant limb-girdle muscular dystrophy associated with conduction defects (LGMD1B): a description of 8 new families with the LMNA gene mutations Rev Neurol (Paris) 2005;161(1):42–54 239 Gaul C, Deschauer M, Tempelmann C, et al Cardiac involvement in limb-girdle muscular dystrophy 2i J Neurol 2006;253(10):1317– 1322 240 Brook JD, McCurrach ME, Harley HG, et al Molecular basis of myotonic dystrophy: expansion of a trinucleotide (CTG) repeat at the 3’ end of a transcript encoding a protein kinase family member Cell 1992;68(4):799–808 241 Nishioka SA, Martinelli Filho M, Marie S, Zatz M, Costa R Myotonic dystrophy and heart disease; behavior of arrhythmic events and conduction disturbances Arq Bras Cardiol 2005;84(4):330–336 242 Bharati S, Bump FT, Bauernfiend R, Lev M Dystrophica myotonia Correlative electrocardiographic, electrophysiologic and